ClinicalTrials.gg
CompletedNCT03783442Updated Jul 29, 2025Results posted

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

A Phase 3 interventional study of Cisplatin and Oxaliplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Completed at 124 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
649
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.

Enrollment
Largest of 23
649 · median 50
Started
2018
with 1 other
Phase 3
3 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
5 of 23
BeiGene

Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one has the largest enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 2nd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Pathologically (histologically) confirmed diagnosis of ESCC
  2. Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced recurrent or disease (per American Joint Committee on Cancer 7th Edition), if there is prior /adjuvant therapy with platinum-based chemotherapy, a treatment-free interval of at least 6 months is required.

Key Exclusion Criteria:

  1. Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation
  2. Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC
  3. Received prior therapies targeting programmed cell death protein-1 (), programmed cell death protein ligand-1 (PD-L1) or PD-L2
  4. Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta)
  5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention ( recurrence requiring an additional intervention within 2 weeks of intervention)
  6. Evidence of complete esophageal obstruction not amenable to treatment
  7. Unintentional weight loss ≥ 5% within one month prior to randomization or Nutritional Risk Index (NRI) \< 83.5 per investigator's choice
  8. Locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy per local investigator.
  9. Participants with untreated chronic or chronic hepatitis B virus (HBV) carriers whose HBV DNA is ≥ 500 IU/mL or participants with active virus (HCV)

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
649 participants (actual)

Study arms

  • Experimental
    Tislelizumab + Chemotherapy

    Participants received tislelizumab 200 milligrams (mg) administered intravenously (IV) on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons. Chemotherapy options were a platinum agent (cisplatin 60-80 mg/m² intravenously on Day 1 or oxaliplatin 130 mg/m² intravenously on Day 1) combined with a fluoropyrimidine (fluorouracil \[750-800 mg/m² intravenously on Days 1-5\] or capecitabine \[1000 mg/m² orally twice daily on Days 1-14\]) or paclitaxel (175 mg/m² intravenously on Day 1).

    Drug: Cisplatin · Drug: Oxaliplatin · Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Paclitaxel · Biological: Tislelizumab

  • Active comparator
    Placebo + Chemotherapy

    Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons. Chemotherapy options were a platinum agent (cisplatin 60-80 mg/m² intravenously on Day 1 or oxaliplatin 130 mg/m² intravenously on Day 1) combined with a fluoropyrimidine (fluorouracil \[750-800 mg/m² intravenously on Days 1-5\] or capecitabine \[1000 mg/m² orally twice daily on Days 1-14\]) or paclitaxel (175 mg/m² intravenously on Day 1).

    Drug: Cisplatin · Drug: Oxaliplatin · Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Paclitaxel · Drug: Placebo

Interventions

  • Cisplatin 60-80 mg/m² administered by intravenous infusion every 3 weeks. Cisplatin was used as the platinum agent in China, Taiwan, and Japan.

  • Oxaliplatin 130 mg/m² administered by intravenous infusion every 3 weeks.

  • Fluorouracil 750-800 mg/m² administered by intravenous infusion on Days 1-5 of each treatment cycle.

  • Capecitabine 1000 mg/m² administered orally twice daily on Days 1-14 of each treatment cycle

  • Paclitaxel 175 mg/m² administered by intravenous infusion every 3 weeks.

  • BiologicalTislelizumab

    Tislelizumab 200 mg administered by intravenous infusion every 3 weeks.

    Also known as: BGB-A317, TEVIMBRA

  • DrugPlacebo

    Placebo to match tislelizumab administered by intravenous infusion every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority.

    Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or unequivocal progression of existing nontarget lesions, or the appearance of 1 or more new lesions. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.

    Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1. Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the neck, chest, and abdomen. CR: Disappearance of all target and nontarget lesions with no new lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. PR: Disappearance of all target lesions with persistence of 1 or more nontarget lesion(s), no new lesions, and/or maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis (data cutoff date of 28 February 2022).

    Time frame: Response was assessed every 6 weeks for the first 48 weeks, then every 9 weeks thereafter; up to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.

  3. Overall Survival (OS) in Participants With a PD-L1 Score ≥ 10%

    OS is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.

    Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.

  4. Duration of Response (DOR)

    DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.

    Time frame: From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.

  5. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Oesophageal Cancer 18 Question Module (QLQ-OES18) Dysphagia, Eating, Reflux, Pain, and Index Scores

    The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (trouble swallowing saliva, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated as the average of the items that contribute to the scale, then transformed to a scale from 0 to 100. The OES18 index score is calculated as the average of the 4 multi-item subscales and 6 single-item subscales. Higher scores indicate a higher level of symptomatology or problems.

    Time frame: Baseline, Cycle 6 (Week 15)

  6. Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) and Physical Functioning Scales

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

    Time frame: Baseline, Cycle 6 (Week 15)

  7. Change From Baseline in EORTC QLQ-C30 Fatigue Scale

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.

    Time frame: Baseline, Cycle 6 (Week 15)

  8. Change From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS)

    The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline, Cycle 6 (Week 15)

  9. Number of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.

    Time frame: From first dose of study drug up to 30 days after last dose; maximum time on treatment was 63.5 months.

07

Results

Posted Nov 7, 2023

Participant flow

This study was conducted at 162 centers in 16 countries/regions across Asia, Europe, North America, and Oceania.

Participant flow — Overall Study
MilestoneTislelizumab + ChemotherapyPlacebo + Chemotherapy
Started326323
Treated324321
Completed00
Not completed326323
Withdrew: Death252268
Withdrew: Withdrawal by subject1921
Withdrew: Lost to follow-up76
Withdrew: Sponsor ended study4828

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority.

Time frame:
From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Reported as:
Median · months
Overall Survival (OS)
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Overall Survival (OS)17.2 (15.8 to 20.1)10.6 (9.3 to 12.1)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Stratified Log-rank Test · p = <0.0001 · Stratified hazard ratio: 0.66 · 95% CI 0.54 to 0.80Stratified Hazard ratio was based on Cox regression model including treatment arm as a covariate and stratified by pooled geographic region (Asia vs. Rest of World), prior definitive therapy and Investigator choice of chemotherapy as strata.
SecondaryProgression-Free Survival (PFS)

Progression-free survival is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, or unequivocal progression of existing nontarget lesions, or the appearance of 1 or more new lesions. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.

Time frame:
From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Progression-Free Survival (PFS)7.3 (6.9 to 8.3)5.6 (4.9 to 6.0)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Stratified Log-rank test · p = <0.0001 · Stratified hazard ratio: 0.62 · 95% CI 0.52 to 0.75Stratified Hazard ratio was based on Cox regression model including treatment arm as a covariate and stratified by pooled geographic region (Asia vs. Rest of World), prior definitive therapy and Investigator choice of chemotherapy as strata.
SecondaryObjective Response Rate (ORR)

ORR is defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) assessed by the investigator per RECIST v1.1. Tumor assessments included computed tomography (CT) scans or magnetic resonance imaging (MRI), with preference for CT, of the neck, chest, and abdomen. CR: Disappearance of all target and nontarget lesions with no new lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \< 10 mm. PR: Disappearance of all target lesions with persistence of 1 or more nontarget lesion(s), no new lesions, and/or maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis (data cutoff date of 28 February 2022).

Time frame:
Response was assessed every 6 weeks for the first 48 weeks, then every 9 weeks thereafter; up to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Objective Response Rate (ORR)63.5 (58.0 to 68.7)42.4 (37.0 to 48.0)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.38 · 95% CI 1.73 to 3.27Odds ratio was calculated using the Cochran-Mantel-Haenszel method, stratified by pooled geographic region, prior definitive therapy, and Investigator choice of chemotherapy.
SecondaryOverall Survival (OS) in Participants With a PD-L1 Score ≥ 10%

OS is defined as the time from the date of randomization until the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.

Time frame:
From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Reported as:
Median · months
Overall Survival (OS) in Participants With a PD-L1 Score ≥ 10%
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Overall Survival (OS) in Participants With a PD-L1 Score ≥ 10%16.6 (15.3 to 24.4)10.0 (8.6 to 13.3)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Stratified Log-rank test · p = 0.0029 · Stratified hazard ratio: 0.62 · 95% CI 0.44 to 0.87Stratified Hazard ratio was based on Cox regression model including treatment arm as a covariate and stratified by pooled geographic region (Asia vs. Rest of World), prior definitive therapy and Investigator choice of chemotherapy as strata.
SecondaryDuration of Response (DOR)

DOR is defined as the time from the first determination of an objective response until the first documentation of progression assessed by the investigator per RECIST v1.1 or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method. Primary analysis (data cut-off date of 28 February 2022) was the pre-defined analysis at which the primary endpoint was tested for superiority. Testing for all secondary efficacy endpoints was conducted at the time of the primary analysis.

Time frame:
From randomization to the primary analysis cutoff date of 28 February 2022; maximum time on follow-up was 3 years and 2 months.
Reported as:
Median · months
Duration of Response (DOR)
monthsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Duration of Response (DOR)7.1 (6.1 to 8.1)5.7 (4.4 to 7.1)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Oesophageal Cancer 18 Question Module (QLQ-OES18) Dysphagia, Eating, Reflux, Pain, and Index Scores

The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (trouble swallowing saliva, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated as the average of the items that contribute to the scale, then transformed to a scale from 0 to 100. The OES18 index score is calculated as the average of the 4 multi-item subscales and 6 single-item subscales. Higher scores indicate a higher level of symptomatology or problems.

Time frame:
Baseline, Cycle 6 (Week 15)
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Oesophageal Cancer 18 Question Module (QLQ-OES18) Dysphagia, Eating, Reflux, Pain, and Index Scores
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Dysphagia-0.5 (-4.7 to 3.7)-4.9 (-9.4 to -0.5)
Eating-0.9 (-3.1 to 1.3)-1.5 (-3.8 to 0.9)
Reflux-1.3 (-3.2 to 0.7)0.2 (-1.9 to 2.2)
Pain-5.2 (-6.7 to -3.7)-3.3 (-4.9 to -1.8)
Index Score-1.0 (-2.2 to 0.3)-0.6 (-1.9 to 0.7)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Mixed Models Analysis · p = 0.1372 · Least squares (ls) mean difference: 4.4 · 95% CI -1.4 to 10.3Based on a mixed effect model analysis with QLQ-OES18 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Mixed Models Analysis · p = 0.7130 · Ls mean difference: 0.6 · 95% CI -2.5 to 3.7Based on a mixed effect model analysis with QLQ-OES18 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Mixed Models Analysis · p = 0.3001 · Ls mean difference: -1.4 · 95% CI -4.1 to 1.3Based on a mixed effect model analysis with QLQ-OES18 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.9 · 95% CI -3.9 to 0.2Based on a mixed effect model analysis with QLQ-OES18 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -0.4 · 95% CI -2.1 to 1.4Based on a mixed effect model analysis with QLQ-OES18 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) and Physical Functioning Scales

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

Time frame:
Baseline, Cycle 6 (Week 15)
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) and Physical Functioning Scales
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Global Health Status/ QOL-0.3 (-2.3 to 1.8)-3.6 (-5.8 to -1.4)
Physical Functioning-4.8 (-6.6 to -3.0)-7.3 (-9.2 to -5.4)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: 3.3 · 95% CI 0.4 to 6.2Based on a mixed effect model analysis, with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: 2.6 · 95% CI 0.0 to 5.1Based on a mixed effect model analysis, with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
SecondaryChange From Baseline in EORTC QLQ-C30 Fatigue Scale

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. The fatigue symptom scale includes 3 items and ranges from 0 to 100, where higher scores indicate a higher level of symptoms.

Time frame:
Baseline, Cycle 6 (Week 15)
Reported as:
Least squares mean · score on a scale
Change From Baseline in EORTC QLQ-C30 Fatigue Scale
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Change From Baseline in EORTC QLQ-C30 Fatigue Scale8.0 (5.7 to 10.4)9.4 (6.9 to 11.9)
Statistical analysis
  • Tislelizumab + Chemotherapy vs Placebo + Chemotherapy · Ls mean difference: -1.4 · 95% CI -4.7 to 1.9Based on a mixed effect model analysis with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
SecondaryChange From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS)

The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline, Cycle 6 (Week 15)
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS)
score on a scaleTislelizumab + ChemotherapyPlacebo + Chemotherapy
Change From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS)-1.1 ± 15.82-3.1 ± 14.01
SecondaryNumber of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose met any of the following criteria: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement.

Time frame:
From first dose of study drug up to 30 days after last dose; maximum time on treatment was 63.5 months.
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTislelizumab + ChemotherapyPlacebo + Chemotherapy
Treatment-emergent adverse event323319
Serious adverse events160128

Adverse events

Collected over All-cause mortality was assessed from randomization until the end of study, maximum time on study was 63.6 months. Adverse events were assessed from first dose of study drug to 30 days after last dose, maximum time on treatment was 63.5 months.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab + Chemotherapy252/326 (77.3%)160/324 (49.4%)321/324 (99.1%)
Placebo + Chemotherapy268/323 (83%)128/321 (39.9%)314/321 (97.8%)
Most frequent serious events
Showing 10 of 186
Most frequent serious events
EventTislelizumab + ChemotherapyPlacebo + Chemotherapy
PneumoniaInfections and infestations19/32423/321
DysphagiaGastrointestinal disorders17/3248/321
NeutropeniaBlood and lymphatic system disorders1/3247/321
DiarrhoeaGastrointestinal disorders7/3243/321
Oesophageal stenosisGastrointestinal disorders7/3242/321
VomitingGastrointestinal disorders7/3245/321
AnaemiaBlood and lymphatic system disorders6/3246/321
General physical health deteriorationGeneral disorders6/3244/321
Decreased appetiteMetabolism and nutrition disorders6/3242/321
HyponatraemiaMetabolism and nutrition disorders6/3242/321
Most frequent other events
Showing 10 of 88
Most frequent other events
EventTislelizumab + ChemotherapyPlacebo + Chemotherapy
AnaemiaBlood and lymphatic system disorders193/324180/321
White blood cell count decreasedInvestigations143/324157/321
Neutrophil count decreasedInvestigations153/324155/321
Decreased appetiteMetabolism and nutrition disorders142/324124/321
NauseaGastrointestinal disorders122/324136/321
ConstipationGastrointestinal disorders102/324101/321
Weight decreasedInvestigations97/32491/321
DiarrhoeaGastrointestinal disorders88/32476/321
VomitingGastrointestinal disorders68/32486/321
HypoalbuminaemiaMetabolism and nutrition disorders75/32460/321

Baseline characteristics

Intent-to-treat (ITT) analysis set included all randomized participants

Age, Continuous
Age, Continuous(years)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Median64.0 (26 to 84)65.0 (40 to 84)64.0 (26 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Female444286
Male282281563
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
American Indian or Alaska Native011
Asian243243486
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7976155
More than one race000
Unknown or Not Reported437
Geographic Region
Geographic Region(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Asia (excluding Japan)210210420
Japan333366
Rest of World8380163
Prior Definitive Therapy
Prior Definitive Therapy(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Yes152150302
No174173347
Investigator Chosen Chemotherapy
Investigator Chosen Chemotherapy(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
Platinum with Fluoropyrimidine147146293
Platinum with Paclitaxel179177356
Programmed Cell Death Protein Ligand-1 (PD-L1) Expression
Programmed Cell Death Protein Ligand-1 (PD-L1) Expression(Participants)Tislelizumab + ChemotherapyPlacebo + ChemotherapyTotal
PD-L1 Score ≥ 10%116107223
PD-L1 Score < 10%151168319
Unknown5948107
08

Study locations

124 sites
  • Smilow Cancer Hospital At Yale
    New Haven, Connecticut 06510-3220, United States
  • Renovatio Clinical
    The Woodlands, Texas 77380-3476, United States
  • Coffs Harbour Base Hospital
    Coffs Harbour, New South Wales 2450, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
  • Az Sint Jan Brugge
    Bruges, 8000, Belgium
  • Grand Hopital de Charleroi Site Notre Dame
    Charleroi, 6000, Belgium
  • UZ GENT
    Ghent, 9000, Belgium
  • University Hospitals Leuven
    Leuven, 3000, Belgium
  • Chc Montlegia
    Liège, 4000, Belgium
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • Anhui Provincial Cancer Hospital Aka West Branch of Anhui Province Hospital
    Hefei, Anhui 230088, China
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • The Fifth Medical Center of Chinese Pla General Hospital
    Beijing, Beijing Municipality 100071, China
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Quanzhou First Affliated Hospital of Fujian Medical University
    Quanzhou, Fujian 362000, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
  • The First Affiliated Hospital, Sun Yat Sen University
    Guangzhou, Guangdong 510080, China
  • The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
    Guangzhou, Guangdong 510405, China
  • Guangdong Province Traditional Chinese Medical Hospitsal
    Guangzhou, Guangdong 510655, China
  • The Sixth Affiliated Hospital, Sun Yat Sen University
    Guangzhou, Guangdong 510655, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • The Tumor Hospital Affiliated to Guangxi Medical University
    Nanning, Guangxi 530021, China
  • Hainan General Hospital
    Haikou, Hainan 570206, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441021, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • The First Peoples Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Nantong Tumor Hospital Branch North
    Nantong, Jiangsu 226000, China
  • Affiliated Hospital of Jiangnan University North Campus (Wuxi Fourth Peoples Hospital )
    Wuxi, Jiangsu 214062, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221000, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Linyi Cancer Hospital
    Linyi, Shandong 276001, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai Municipality 200000, China
  • Shanxi Provincial Peoples Hospital
    Taiyuan, Shanxi 030012, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
  • Fakultni Thomayerova Nemocnice
    Prague, 140 59, Czechia
  • Chru de Brest Hopital Cavale Blanche
    Brest, 29200, France
  • Chu Besancon Hopital Jean Minjoz
    Doubs, 25030, France
  • Hopital Franco Britannique
    LevalloisPerret, 92300, France
  • Centre Oscar Lambret
    Lille, 59000, France
  • Centre Leon Berard
    Lyon, 69373, France
  • Hopital Saint Antoine Service Dhepato Gastro Enterologie
    Paris, 75012, France
  • Hopital Europeen Georges Pompidou
    Paris, 75015, France
  • Chu Bordeaux Hopital Haut Leveque
    Pessac, 33600, France
  • Chu de Poitiers Site de La Mileterie
    Poitiers, 86000, France
  • Centre de Lutte Contre Le Cancer Institut de Cancerologie de Louest Rene Gauducheau
    SaintHerblain, 44805, France
  • Universitatsklinikum Hamburg Eppendorf
    Hamburg, 20251, Germany
  • Slk Kliniken Heilbronn Gmbh Klinik Fur Radiologie, Minimalinvasive Therapien Und Nuklearmedizin
    Heilbronn, 74078, Germany
  • Universitares Krebszentrum Leipzig
    Leipzig, 04103, Germany
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
    Meldola, 47014, Italy
  • Istituto Europeo Di Oncologia
    Milan, 20141, Italy
  • Istituto Nazionale Tumori Fondazione G Pascale
    Naples, 80131, Italy
  • Iov Istituto Oncologico Veneto Irccs
    Padova, 35128, Italy
  • Azienda Ospedaliera Universitaria Delle Marche
    Torrette, 60020, Italy
  • Akita University Hospital
    Akitashi, Akita 010-8543, Japan
  • National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • Nho Kyushu Cancer Center
    Fukuoka, Fukuoka 811-1395, Japan
  • National Hospital Organization Kyushu Medical Center
    Fukuokacity, Fukuoka 810-8563, Japan
  • Hyogo Cancer Center
    AkashiShi, Hyōgo 673-0021, Japan
  • Johas Kansai Rosai Hospital
    Amagasakishi, Hyōgo 660-8511, Japan
  • Kanagawa Cancer Center
    Yokohama, Kanagawa 241-8515, Japan
  • University Hospital, Kyoto Prefectural Univ of Medicine
    KyotoShi, Kyoto 602-8566, Japan
  • Osaka International Cancer Institute
    OsakaShi, Osaka 541-8567, Japan
  • The University of Osaka Hospital
    Suitashi, Osaka 565-0871, Japan
  • Saitama Cancer Center
    Kitaadachigun, Saitama 362-0806, Japan
  • National Cancer Center Hospital
    ChuoKu, Tokyo 104-0045, Japan
  • Hiroshima University Hospital
    Hiroshima, 734-0037, Japan
  • Kumamoto University Hospital
    Kumamoto, 860-8556, Japan
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
  • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
    Brzozów, 36-200, Poland
  • Szpital Wojewodzki Im Mikoaja Kopernika W Koszalinie
    Koszalin, 75-581, Poland
  • Spzoz Mswia Z Warminsko Mazurskim Centrum Onkologii
    Olsztyn, 10-228, Poland
  • Narodowy Instytut Onkologii Im Marii Skodowskiej Curie Pastwowy Instytut Badawczy
    Warsaw, 02-781, Poland
  • Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
    ClujNapoca, 400015, Romania
  • Medisprof Cancer Center
    ClujNapoca, 400641, Romania
  • Radiotherapy Center Cluj
    ClujNapoca, 407280, Romania
  • Sc Centrul de Oncologie Sf Nectarie Srl
    Craiova, 200347, Romania
  • Arkhangelsk Regional Clinical Oncological Dispensary
    Arkhangelsk, Arkhangelskaya oblast 163045, Russia
  • Rbih Ivanovo Regional Oncological Dispensary
    Ivanovo, Ivanovo Oblast 153040, Russia
  • State Budget Healthcare Institution Leningrad Regional Clinical Oncologic Dispensary
    Kuzmolovsky, Leningradskaya Oblast' 188663, Russia
  • Orenburg Regional Clinical Oncology Center
    Orenburg, Orenburg Oblast 460021, Russia
  • Rostov State Medical University
    RostovonDon, Rostov Oblast 344022, Russia
  • Pavlov First Saint Petersburg State Medical University
    SaintPetersburg, Sankt-Peterburg 197022, Russia

Showing the first 100 of 124 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang J, Wu X, Yao Y, Shen L, Kojima T, Gotovkin E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Lin CY, Wang L, Shi J, Li L, Yoon HH. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023 May;24(5):483-495. doi: 10.1016/S1470-2045(23)00108-0. Epub 2023 Apr 17. PubMed 37080222 ↗
  • Xu J, Kato K, Hubner R, Park SR, Kojima T, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca P, Wu H, Wang L, Yan S, Shi J, Kadva A, Yoon HH. First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression >/= 1%: A Retrospective Analysis of RATIONALE-306. Adv Ther. 2025 May;42(5):2269-2284. doi: 10.1007/s12325-025-03115-9. Epub 2025 Mar 13. PubMed 40075024 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Feb 2022, 38 months.

Results were first posted in Nov 2023, 1 year 8 months after primary completion.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2018
First posted
Dec 21, 2018
StartActual
Dec 11, 2018
Primary completionActual
Feb 28, 2022
CompletionActual
Aug 22, 2024
Results first posted
Nov 7, 2023
Last update
Jul 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03783442
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Dec 21, 2018
Start date
Dec 11, 2018
Primary completion
Feb 28, 2022
Completion
Aug 22, 2024
Results posted
Nov 7, 2023
Last update
Jul 29, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion